Veriton Pharma

Veriton Pharma is a specialised pharmaceutical company, acquired by SERB Pharmaceuticals in 2020, that develops and commercialises tailored therapies for unmet medical needs, with a core focus on CNS disorders like epilepsy and rare paediatric conditions. It operates a hybrid portfolio of licensed prescription products and a broad range of unlicensed 'specials', supported by a trusted supply chain and direct NHS engagement. The company benefits from SERB's global infrastructure and antidote portfolio, positioning it as a key player in niche therapeutic areas with a strong service-oriented model for hospitals and prescribers worldwide.

Specialised formulation development and manufacturing expertise for licensed and unlicensed ('specials') medicines, particularly in complex dosage forms for CNS and paediatric conditions. Integrated within SERB's full pharmaceutical development, manufacturing, and global supply chain platform.

Operates in the niche but competitive market of specialised pharmaceuticals and 'specials'. Competitors include other specialty pharma companies with CNS focus, hospital compounding pharmacies, and generic manufacturers of established epilepsy drugs. Differentiates through deep NHS relationships, a service-oriented model, and the quality assurance of regulated manufacturing.